FRANKFURT (Reuters) -Swiss drugmaker Novartis on Thursday projected currency-adjusted sales growth of 5% to 6% until 2030, supported by higher peak-revenue prospects for its cancer drugs Kisqali and Scemblix to offset losses from expiring patents.

In a statement ahead of an investor event, the company lifted the peak sales forecast for Kisqali, used to treat a common type of breast cancer, to at least $10 billion from a previous estimate of $8 billion.

For leukaemia drug Scemblix, Novartis now expects peak sales of at least $4 billion, up from at least $3 billion.

The company said its eight most promising approved drugs each carry peak-sales potential of $3 billion to $10 billion.

Last month, it moved to acquire Avidity Biosciences in a $12 billion deal to add muscle-disorder treatment

See Full Page